Wall Street brokerages expect Impax Laboratories Inc (NASDAQ:IPXL) to announce earnings per share (EPS) of $0.17 for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Impax Laboratories’ earnings, with the lowest EPS estimate coming in at $0.11 and the highest estimate coming in at $0.22. Impax Laboratories reported earnings per share of $0.11 during the same quarter last year, which would suggest a positive year-over-year growth rate of 54.5%. The company is scheduled to issue its next quarterly earnings results on Wednesday, May 9th.
On average, analysts expect that Impax Laboratories will report full year earnings of $1.27 per share for the current year, with EPS estimates ranging from $1.20 to $1.32. For the next financial year, analysts forecast that the company will post earnings of $1.67 per share, with EPS estimates ranging from $1.63 to $1.74. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Impax Laboratories.
Impax Laboratories (NASDAQ:IPXL) last announced its quarterly earnings data on Thursday, March 1st. The specialty pharmaceutical company reported $0.11 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.12 by ($0.01). Impax Laboratories had a negative net margin of 60.49% and a positive return on equity of 10.42%. The company had revenue of $182.90 million during the quarter, compared to the consensus estimate of $199.13 million. During the same quarter in the previous year, the firm posted $0.16 EPS. The business’s revenue for the quarter was down 7.8% compared to the same quarter last year.
Shares of Impax Laboratories (NASDAQ:IPXL) opened at $20.75 on Wednesday. The company has a debt-to-equity ratio of 4.11, a current ratio of 1.96 and a quick ratio of 1.52. Impax Laboratories has a 12-month low of $8.80 and a 12-month high of $25.70. The firm has a market capitalization of $1,540.00, a P/E ratio of -3.18, a price-to-earnings-growth ratio of 0.94 and a beta of 1.01.
Institutional investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio grew its stake in Impax Laboratories by 12.7% in the second quarter. Public Employees Retirement System of Ohio now owns 6,911 shares of the specialty pharmaceutical company’s stock worth $111,000 after purchasing an additional 780 shares during the period. Xact Kapitalforvaltning AB purchased a new stake in Impax Laboratories in the fourth quarter worth $198,000. Amalgamated Bank purchased a new stake in Impax Laboratories in the third quarter worth $201,000. Quantbot Technologies LP grew its stake in Impax Laboratories by 279.0% in the third quarter. Quantbot Technologies LP now owns 10,031 shares of the specialty pharmaceutical company’s stock worth $203,000 after purchasing an additional 7,384 shares during the period. Finally, Stevens Capital Management LP purchased a new stake in Impax Laboratories in the third quarter worth $203,000. Institutional investors own 90.40% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “$0.17 Earnings Per Share Expected for Impax Laboratories Inc (IPXL) This Quarter” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/03/14/0-17-earnings-per-share-expected-for-impax-laboratories-inc-ipxl-this-quarter.html.
Impax Laboratories Company Profile
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.